- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | Marvel Biosciences Corp: Marvel Biosciences obtains financing to develop drug | 2 | Stockwatch | ||
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 315 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders | 106 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the... ► Artikel lesen | |
| 04.02. | Marvel Biosciences Corp: Marvel Biosciences receives Japanese patent for MB-204 | 1 | Stockwatch | ||
| 03.02. | Marvel Biosciences Corp.: Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 | 284 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or... ► Artikel lesen | |
| 22.12.25 | Toronto Stock Exchange: Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite | 381 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Rod Matheson, Chief Executive Officer, and Mark Williams, Chief Strategy Officer, from Marvel Biosciences Corp. (the "Company") (TSXV: MRVL)... ► Artikel lesen | |
| 11.11.25 | Marvel Biosciences Corp: Marvel Biosciences grants 35,697 deferred share units | 2 | Stockwatch | ||
| 10.11.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 413 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.10.25 | Marvel Biosciences Corp: Marvel Biosciences accelerates expiry of warrants | 3 | Stockwatch | ||
| 03.10.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Acceleration of Warrant Expiry Date | 447 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is... ► Artikel lesen | |
| 18.08.25 | Marvel Biosciences Corp.: Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204 | 509 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 12.08.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 581 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 13.05.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement | 697 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 02.05.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Second Tranche of Private Placement | 388 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased... ► Artikel lesen | |
| 30.04.25 | Marvel Biosciences Corp.: Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment | 241 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 16.04.25 | Marvel Biosciences Corp.: Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting | 199 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased... ► Artikel lesen | |
| 14.04.25 | Marvel Biosciences Corp.: Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference | 211 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 28.03.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Private Placement | 780 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased... ► Artikel lesen | |
| 17.03.25 | Marvel Biosciences Corp.: Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome | 366 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 13.03.25 | Marvel Biosciences Corp.: Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide | 314 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | +1,38 % | Qiagen: Analysten sehen Wettbewerbssorgen als übertrieben | Nach Gesprächen mit dem Qiagen-Management auf Analysten-Konferenzen in den USA stufen Analysten die Aktie des Diagnostikspezialisten weiterhin positiv ein. Jefferies beließ es bei einer Kaufempfehlung... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,98 | -2,63 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS... ► Artikel lesen | |
| ARCELLX | 113,80 | -0,05 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| BIONTECH | 93,10 | -0,21 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,26 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 14,750 | -79,74 % | Novartis Pharma AG: Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy | Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar... ► Artikel lesen | |
| CARDIO DIAGNOSTICS | 6,490 | +24,33 % | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 336,75 | -1,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,820 | -3,48 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| RELAY THERAPEUTICS | 10,250 | +12,02 % | Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ADMA BIOLOGICS | 15,580 | +2,70 % | ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance | ||
| EDGEWISE THERAPEUTICS | 30,450 | +2,77 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,870 | -1,55 % | Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval | ||
| PRIME MEDICINE | 4,630 | +5,71 % | Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as... ► Artikel lesen |
MARVEL BIOSCIENCES CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.